Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...

Number 5: The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases. Number 4: February brought ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

Sandoz pointed to the uptake of its Humira biosimilar Hyrimoz in the US through a private-label agreement with CVS biosimilar subsidiary Cordavis as one of the drivers of its biosimilar business ...

Pharmacy benefit managers take considerably different approaches to managing patient access to biosimilars, or cheaper ...

Opens in a new tab or window Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the ...